Clinical Trial: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi(R), and US-licensed Skyrizi(R) in Healthy Adult Participants

U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258745) titled 'Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi(R), and US-licensed Skyrizi(R) in Healthy Adult Participants' on Nov. 17.

Brief Summary: This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi in healthy adult participants.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Psoriasis

Intervention: BIOLOGICAL: SKYRIZI

EU-sourced

BIOLOGICAL: SKYRIZI

US-licensed...